Phase 2 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with breast cancer (confirmed by biopsy from the original tumour site or a metastatic site) that has spread to the membranes surrounding the brain and spinal cord (leptomeningeal metastasis), confirmed by MRI scan or cerebrospinal fluid testing — brain involvement may or may not also be present.
- People whose general health and ability to function meets a minimum score of 60 on the Karnofsky Performance Scale, a medical measure of how well a person can carry out daily activities (confirm with trial site).
- People whose blood counts meet the required levels, including enough white blood cells, platelets, and red blood cells, as measured by a recent blood test.
- People whose kidneys are working well enough, based on blood and/or urine test results falling within the required ranges.
- People whose liver is working well enough, based on blood test results falling within the required ranges (slightly different thresholds may apply if the cancer has spread to the liver, or if there is a history of a condition called Gilbert's syndrome).
- Women who could become pregnant, and men whose partners could become pregnant, who agree to use effective contraception throughout the study and for 7 months after the last dose of the study treatment.
Who may not be able to join:
- People who have another active cancer unrelated to their breast cancer, unless it is a type of skin cancer (basal cell or squamous cell carcinoma) or a non-invasive cancer (in situ carcinoma) that has already been fully treated.
- People who are intolerant to, or who have had a severe allergic or hypersensitivity reaction (Grade 3 or higher) to any ingredients in the study drug, including sulfobutylether-β-cyclodextrin, mefenamic acid, bendamustine, chloramphenicol, or any chemotherapy medicines in the nitrogen mustard family.
- People who have received a live vaccine or an experimental medication within the 30 days before the study treatment is due to start.
- People who are pregnant or currently breastfeeding.
- People who have any other condition that the trial doctor judges would make participation in the study unsuitable (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Binghe Xu, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phone: 021-50800906
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
OS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.